Literature summary extracted from

Zhu, S.; Zheng, G.
Dynamic kinetic resolution of Vince lactam catalyzed by gamma-lactamases a mini-review (2018), J. Ind. Microbiol. Biotechnol., 45, 1017-1031 .

Application

EC Number	Application	Comment	Organism
3.5.2.B2	drug development	the use of gamma-lactamase as a biocatalyst offers an attractive and environmentally friendly approach for the synthesis of a broad range of carbocyclic nucleoside drugs. The enzyme can be used for enzymatic kinetic resolution of racemic Vince lactam (2-azabicyclo[2.2.1]hept-5-en-3-one) in the industry. Optically pure enantiomers and their hydrolytic products are widely employed as key chemical intermediates for developing a wide range of carbocyclic nucleoside medicines, including US FDA-approved drugs peramivir and abacavir	Escherichia coli
3.5.2.B2	drug development	the use of gamma-lactamase as a biocatalyst offers an attractive and environmentally friendly approach for the synthesis of a broad range of carbocyclic nucleoside drugs. The enzyme can be used for enzymatic kinetic resolution of racemic Vince lactam (2-azabicyclo[2.2.1]hept-5-en-3-one) in the industry. Optically pure enantiomers and their hydrolytic products are widely employed as key chemical intermediates for developing a wide range of carbocyclic nucleoside medicines, including US FDA-approved drugs peramivir and abacavir	Bradyrhizobium japonicum
3.5.2.B2	drug development	the use of gamma-lactamase as a biocatalyst offers an attractive and environmentally friendly approach for the synthesis of a broad range of carbocyclic nucleoside drugs. The enzyme can be used for enzymatic kinetic resolution of racemic Vince lactam (2-azabicyclo[2.2.1]hept-5-en-3-one) in the industry. Optically pure enantiomers and their hydrolytic products are widely employed as key chemical intermediates for developing a wide range of carbocyclic nucleoside medicines, including US FDA-approved drugs peramivir and abacavir	Pseudomonas fluorescens
3.5.2.B2	drug development	the use of gamma-lactamase as a biocatalyst offers an attractive and environmentally friendly approach for the synthesis of a broad range of carbocyclic nucleoside drugs. The enzyme can be used for enzymatic kinetic resolution of racemic Vince lactam (2-azabicyclo[2.2.1]hept-5-en-3-one) in the industry. Optically pure enantiomers and their hydrolytic products are widely employed as key chemical intermediates for developing a wide range of carbocyclic nucleoside medicines, including US FDA-approved drugs peramivir and abacavir	Delftia acidovorans
3.5.2.B2	drug development	the use of gamma-lactamase as a biocatalyst offers an attractive and environmentally friendly approach for the synthesis of a broad range of carbocyclic nucleoside drugs. The enzyme can be used for enzymatic kinetic resolution of racemic Vince lactam (2-azabicyclo[2.2.1]hept-5-en-3-one) in the industry. Optically pure enantiomers and their hydrolytic products are widely employed as key chemical intermediates for developing a wide range of carbocyclic nucleoside medicines, including US FDA-approved drugs peramivir and abacavir	Rhodococcus erythropolis
3.5.2.B2	drug development	the use of gamma-lactamase as a biocatalyst offers an attractive and environmentally friendly approach for the synthesis of a broad range of carbocyclic nucleoside drugs. The enzyme can be used for enzymatic kinetic resolution of racemic Vince lactam (2-azabicyclo[2.2.1]hept-5-en-3-one) in the industry. Optically pure enantiomers and their hydrolytic products are widely employed as key chemical intermediates for developing a wide range of carbocyclic nucleoside medicines, including US FDA-approved drugs peramivir and abacavir	Burkholderia cepacia
3.5.2.B2	drug development	the use of gamma-lactamase as a biocatalyst offers an attractive and environmentally friendly approach for the synthesis of a broad range of carbocyclic nucleoside drugs. The enzyme can be used for enzymatic kinetic resolution of racemic Vince lactam (2-azabicyclo[2.2.1]hept-5-en-3-one) in the industry. Optically pure enantiomers and their hydrolytic products are widely employed as key chemical intermediates for developing a wide range of carbocyclic nucleoside medicines, including US FDA-approved drugs peramivir and abacavir	Saccharolobus solfataricus
3.5.2.B2	drug development	the use of gamma-lactamase as a biocatalyst offers an attractive and environmentally friendly approach for the synthesis of a broad range of carbocyclic nucleoside drugs. The enzyme can be used for enzymatic kinetic resolution of racemic Vince lactam (2-azabicyclo[2.2.1]hept-5-en-3-one) in the industry. Optically pure enantiomers and their hydrolytic products are widely employed as key chemical intermediates for developing a wide range of carbocyclic nucleoside medicines, including US FDA-approved drugs peramivir and abacavir	Ralstonia solanacearum
3.5.2.B2	drug development	the use of gamma-lactamase as a biocatalyst offers an attractive and environmentally friendly approach for the synthesis of a broad range of carbocyclic nucleoside drugs. The enzyme can be used for enzymatic kinetic resolution of racemic Vince lactam (2-azabicyclo[2.2.1]hept-5-en-3-one) in the industry. Optically pure enantiomers and their hydrolytic products are widely employed as key chemical intermediates for developing a wide range of carbocyclic nucleoside medicines, including US FDA-approved drugs peramivir and abacavir	Rhodococcus globerulus
3.5.2.B2	drug development	the use of gamma-lactamase as a biocatalyst offers an attractive and environmentally friendly approach for the synthesis of a broad range of carbocyclic nucleoside drugs. The enzyme can be used for enzymatic kinetic resolution of racemic Vince lactam (2-azabicyclo[2.2.1]hept-5-en-3-one) in the industry. Optically pure enantiomers and their hydrolytic products are widely employed as key chemical intermediates for developing a wide range of carbocyclic nucleoside medicines, including US FDA-approved drugs peramivir and abacavir	Aeropyrum pernix
3.5.2.B2	drug development	the use of gamma-lactamase as a biocatalyst offers an attractive and environmentally friendly approach for the synthesis of a broad range of carbocyclic nucleoside drugs. The enzyme can be used for enzymatic kinetic resolution of racemic Vince lactam (2-azabicyclo[2.2.1]hept-5-en-3-one) in the industry. Optically pure enantiomers and their hydrolytic products are widely employed as key chemical intermediates for developing a wide range of carbocyclic nucleoside medicines, including US FDA-approved drugs peramivir and abacavir	Nocardia farcinica
3.5.2.B2	drug development	the use of gamma-lactamase as a biocatalyst offers an attractive and environmentally friendly approach for the synthesis of a broad range of carbocyclic nucleoside drugs. The enzyme can be used for enzymatic kinetic resolution of racemic Vince lactam (2-azabicyclo[2.2.1]hept-5-en-3-one) in the industry. Optically pure enantiomers and their hydrolytic products are widely employed as key chemical intermediates for developing a wide range of carbocyclic nucleoside medicines, including US FDA-approved drugs peramivir and abacavir	Delftia sp.
3.5.2.B2	drug development	the use of gamma-lactamase as a biocatalyst offers an attractive and environmentally friendly approach for the synthesis of a broad range of carbocyclic nucleoside drugs. The enzyme can be used for enzymatic kinetic resolution of racemic Vince lactam (2-azabicyclo[2.2.1]hept-5-en-3-one) in the industry. Optically pure enantiomers and their hydrolytic products are widely employed as key chemical intermediates for developing a wide range of carbocyclic nucleoside medicines, including US FDA-approved drugs peramivir and abacavir	Microbacterium hydrocarbonoxydans
3.5.2.B2	drug development	the use of gamma-lactamase as a biocatalyst offers an attractive and environmentally friendly approach for the synthesis of a broad range of carbocyclic nucleoside drugs. The enzyme can be used for enzymatic kinetic resolution of racemic Vince lactam (2-azabicyclo[2.2.1]hept-5-en-3-one) in the industry. Optically pure enantiomers and their hydrolytic products are widely employed as key chemical intermediates for developing a wide range of carbocyclic nucleoside medicines, including US FDA-approved drugs peramivir and abacavir	Pseudomonas granadensis

Organism

EC Number	Organism	UniProt	Comment	Textmining
3.5.2.B2	Aeropyrum pernix	-	-	-
3.5.2.B2	Bradyrhizobium japonicum	-	-	-
3.5.2.B2	Bradyrhizobium japonicum USDA 6	-	-	-
3.5.2.B2	Burkholderia cepacia	-	-	-
3.5.2.B2	Delftia acidovorans	-	-	-
3.5.2.B2	Delftia sp.	-	-	-
3.5.2.B2	Delftia sp. CGMCC 5755	-	-	-
3.5.2.B2	Escherichia coli	-	-	-
3.5.2.B2	Microbacterium hydrocarbonoxydans	-	-	-
3.5.2.B2	Nocardia farcinica	-	-	-
3.5.2.B2	Pseudomonas fluorescens	-	-	-
3.5.2.B2	Pseudomonas fluorescens ENZA 22	-	-	-
3.5.2.B2	Pseudomonas granadensis	-	-	-
3.5.2.B2	Pseudomonas granadensis B6	-	-	-
3.5.2.B2	Ralstonia solanacearum	-	-	-
3.5.2.B2	Ralstonia solanacearum ENZA 20	-	-	-
3.5.2.B2	Rhodococcus erythropolis	-	-	-
3.5.2.B2	Rhodococcus erythropolis PR4	-	-	-
3.5.2.B2	Rhodococcus globerulus	-	-	-
3.5.2.B2	Saccharolobus solfataricus	-	-	-